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ABSTRACT
There has been increased interest in gout in
both academic and clinical practice settings.
Several reasons may explain this. The
prevalence of both hyperuricemia and gout
has risen in the last decades in developed
countries and therefore the burden of gout has
increased. The association of hyperuricemia and
gout with cardiovascular outcomes and the
opportunity of further benefits of intervention
on hyperuricemia have been recently
highlighted in the literature. Imaging
techniques have proven to be useful for
detection of urate deposition, even prior to
the first clinical symptoms, enabling the
evaluation of the extent of deposition and
providing objective measurement of crystal
depletion during urate-lowering treatment.
Treating to target is increasingly used as the
approach to treatment of diverse diseases.
Therefore, different targets have been
recommended for different stages of the
burden of disease and for different stages of
treatment. The final strategic target, to which
any effort should be taken into consideration, is
to completely dissolve urate crystals in tissues
and therefore avoid further symptoms and
structural damage of involved musculoskeletal
structures. In summary, evidence suggest that
an early approach to the treatment of gout and
associated comorbidities is advisable, that new
imaging techniques may help to evaluate both
the burden of deposition and response to urate-
lowering treatment in selected patients, and
finally that the final strategic objective of
healthcare for patients with gout is to
completely resolve urate crystal deposits.
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An increase in the prevalence of both
hyperuricemia and gout has been shown
during the previous decades in developed
countries. The association of hyperuricemia,
but especially of gout, with cardiovascular
outcomes and the opportunity of further
benefits of early intervention have been
recently highlighted. The fact that crystal
deposition and subclinical inflammation
precede the clinical onset of gout may deliver
a new approach to the treatment of
hyperuricemia and gout.
Gout is due to the nucleation and growth of
monosodium urate (MSU) crystals in tissues in
and around the joints, following long-standing
hyperuricemia, that is, serum urate (sUA) above
the saturation threshold.
The sequence of events that occur in the
hyperuricemic patients has been recently
suggested to comprise four stages (Fig. 1) [1].
Hyperuricemia promotes MSU crystal deposits
that are first asymptomatic but can be detected
by imaging techniques such as ultrasound and
dual-energy computed tomography (DECT).
Once formed, MSU crystals can cause acute,
self-limited, inflammatory flares, probably
triggered by crystal shedding from the
cartilage surface into the joint space, where
they can interact with resident cells. If
hyperuricemia persists, MSU crystal deposits
further induce chronic inflammatory responses
that may lead to damage of the joint structures,
the so-called chronic gouty arthritis or chronic
gout, which is usually associated with the
presence of subcutaneous MSU deposits or
tophi. Finally, as deposits grow and
comorbidities increase, gout becomes even
more severe and difficult to treat becoming
what is known as ‘‘refractory gout’’.
Therefore, gout must be viewed as a chronic,
progressive disease if sUA levels are not
appropriately lowered. MSU crystal deposits
Fig. 1 Diagram showing the path from hyperuricemia to
structural joint damage. Long-standing hyperuricemia may
lead to monosodium urate deposits, with no symptoms
and sometimes associated to subclinical inﬂammation;
intermittent acute inﬂammation is caused by crystal shedding
into the joint space, inﬂammation persisting between ﬂares,
bone erosions may appear; untreated or improperly treated
deposition will lead to further persistent inﬂammation,
increase in the number of ﬂares and structural joint damage
with permanent joint space narrowing
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should be considered the prime and most
important target for the management of gout.
By lowering sUA levels at least below 6 mg/dl
(360 lml/L), dissolution of the pathogenic MSU
crystals is achieved and disappearance of
clinical features of gout can be obtained [2, 3].
This chronic disease should be taken seriously,
as it can cause severe damage to joint structures
and has also been associated with poor kidney
and cardiovascular outcomes [4].
Recent data have shown that hyperuricemia
and gout are increasing worldwide [5]. Such an
epidemic has deleterious consequences not only
on joint function, health resources utilization,
and quality of life, but may also increase
cardiovascular mortality. Gouty patients die
mainly from cardiovascular events [6], and
several studies have shown that gout is indeed
an independent cardiovascular risk factor [7–9],
even more when gout is severe [6]. This
independent effect of gout on cardiovascular
mortality adds on frequently associated
comorbidities; although it may reflect to some
extent frequent nonsteroidal anti-inflammatory
drugs (NSAIDs) intake during flares,
inflammation and hyperuricemia are
considered to be the main factors [4].
Asymptomatic hyperuricemia has long been
known to be associated with cardiovascular
morbidity and mortality, but the traditional
view has been that this was due to the
association of well-known cardiovascular risk
factors, as adjustment for associated traditional
risk factors led to the disappearance of the
association between hyperuricemia and
cardiovascular events in the Framingham heart
study [10]. Asymptomatic hyperuricemia has
long been considered as a mere indicator of
associated cardiovascular comorbidities, the
frequency of which correlates with the level of
hyperuricemia [11]. Comorbidities and not
hyperuricemia per se were believed to explain
the increased death rate. This view has been
very much challenged during the last decade, as
recent studies have shown an independent
association of hyperuricemia with
cardiovascular events, although this
association appeared to be weaker than with
gout [4]. Moreover, data have accumulated
which suggests that hyperuricemia plays a role
in the occurrence of hypertension, heart
disease, type 2 diabetes and renal impairment
[4], which would make traditional statistical
adjustments for confounding variables
inaccurate. For example, if hyperuricemia
causes hypertension, adjustment for
hypertension to determine whether
hyperuricemia independently associates with
cardiovascular outcomes makes little sense.
Indeed, hyperuricemia has been shown to
precede hypertension in many prospectively
followed human cohorts [12]. Several animal
studies, using various ways to induce
hyperuricemia, demonstrated that
hyperuricemia induced hypertension in rats
and blood pressure could be corrected by
various urate-lowering drugs if these were
given early [13–15]. Similarly, in
hyperuricemic adolescents with incipient
hypertension or prehypertension, urate-
lowering medications (ULMs) normalized
blood pressure [16, 17]. Hyperuricemia is
frequently associates with type 2 diabetes and
the metabolic syndrome [11], and prospective
human studies have shown that hyperuricemia
again preceded the appearance of diabetes [4].
In rats fed with a fructose-enriched diet,
hyperuricemia and hyperinsulinism developed
and were corrected by urate-lowering
interventions [14]. The detrimental effect of
hyperuricemia on the kidney is suggested by
animal studies [13]. Human studies have shown
that hyperuricemia predicted the appearance of
chronic kidney disease (CKD) [18] and was a
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factor of poor prognosis in many renal diseases
[4]. In addition, small randomized controlled
trials have suggested that sUA lowering might
improve kidney prognosis in CKD patients [4].
The beneficial effect of sUA lowering on
cardiovascular mortality has not been studied in
randomized controlled trials (RCTs). However,
several retrospective studies have concluded
that allopurinol intake was associated with a
decrease in myocardial infarction and mortality
[4, 19], especially when allopurinol was given at
a dose allowing reduction of sUA below 6 mg/dL
[20].
Therefore, despite some ongoing
controversies, the case is strong for
considering hyperuricemia as an independent
cardiovascular risk factor. However, because of
the lack of large RCTs showing that urate
lowering improves cardiovascular mortality,
no drug has been thus far approved, apart
from in Japan, for the management of
asymptomatic hyperuricemia [4].
TAKING A NEW LOOK AT GOUT:
THE ROLE OF IMAGING
IN THE CLINICAL MANAGEMENT
OF GOUT
Imaging techniques have nicely shown the
pathophysiological connection between
hyperuricemia, urate crystal deposition in
tissues, and gout, even prior to the first
clinical symptom. They have been shown to
be sensitive to detect the extent of deposition,
but also sensitive enough to change to provide
objective measurement of crystal depletion
during urate-lowering treatment.
Advanced imaging modalities have provided
important new insights into the mechanisms of
disease and treatment approaches in gout. As
described above, the central feature of gout is
deposition of MSU crystals, and the clinical
manifestations of gout occur due to the
individual’s response to these crystals. The
most widely studied imaging methods that
allow analysis of MSU crystal deposition are
ultrasonography and DECT. On
ultrasonography, MSU crystals overlying the
articular cartilage can be detected as the
‘double contour’ sign [21, 22]. Tophi,
collections of MSU crystals surrounded by an
organized cellular rim and fibrovascular zone
[23], can also be detected by ultrasonography
[21]. Dual-source DECT, a dual-energy
computerized tomography (CT) technique that
includes two X-ray sources and two detectors,
evaluates the different attenuations of the
scanned object to analyze if the chemical
composition of materials includes urate
crystals. In gout, urate can be color-coded for
visualization and measured using automated
volume measurement software [24] (Fig. 2).
A key insight into gout pathogenesis that has
arisen from ultrasonography studies is the
observation that MSU crystals are present in
some people with hyperuricemia, but without
clinical symptoms of gout. It has long been
recognized that although hyperuricemia is
virtually always present in people with gout,
Fig. 2 Three-dimensional volume rendered reconstruction
of a dual-energy CT scan of the right foot in a patient with
tophaceous gout, demonstrating the extent of urate crystal
deposition throughout the foot, and particularly at the 1st
metatarsophalangeal joint and Achilles tendon. Urate
crystals are shown in green
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many people with hyperuricemia do not
develop clinically apparent disease [25].
Therefore, other factors must also contribute
to the development of clinically apparent
disease. Recent studies have shown that in
those with mean serum urate concentrations of
[8 mg/dL, ultrasonographic features of MSU
crystal deposition are present in 17–42 % of
individuals [26–29]. Microscopy studies have
confirmed the presence of MSU crystals in the
majority of those with ultrasonographic
appearances of crystal deposition [26]. Thus, it
seems likely that MSU crystal deposition occurs
as a precursor to clinically apparent disease. At
present, it is unknown whether the presence of
MSU crystals on ultrasonography can predict
development of clinically apparent gout in
individuals with hyperuricemia. It is also
unknown whether interventions to reduce
serum urate concentrations in such individuals
with hyperuricemia and imaging features of
MSU crystal deposition have a role in reducing
the risk of developing recurrent flares or joint
damage associated with gout.
Gout is characterized by recurrent flares of
severe joint inflammation, and most patients are
frequently entirely asymptomatic during
intercritical periods. Microscopy studies have
indicated that MSU crystals are present in
previously inflamed joints in people with gout
and persistent hyperuricemia [30]. Advanced
imaging methods have provided further insight
into these intercritical periods, demonstrating
that imaging features of MSU crystal deposition
are frequently present in people during
intercritical periods or at times when joints are
not acutely inflamed [31]. These findings
reinforce the concept that gout is a chronic
disease of MSU crystal deposition and that
crystal deposition can progress even in the
absence of clinical features of joint
inflammation.
The extent of MSU crystal deposition in
people with gout has also been highlighted by
advanced imaging methods, particularly DECT.
This technique demonstrates many more urate
deposits than can be appreciated by physical
examination [24]. In addition, DECT and
ultrasonography have clarified the patterns of
crystal deposits, particularly in periarticular
sites. A detailed ultrasonography study has
identified both cartilage and tendon areas with
high frequency ([35 %) of MSU crystal
deposition as the 1st metatarsal dorsal
cartilage, patellar tendon, 1st
metatarsophalangeal dorsal recess, triceps
tendon, femoral condyle cartilage, quadriceps
tendon and radiocarpal dorsal recess [32]. In
contrast, other areas are infrequently affected
(\5 %) including the 1st–5th
metacarpophalangeal palmar recess, elbow
posterior recess, deep infrapatellar bursa,
gastrocnemius–semimembranosus bursa, and
5th metacarpophalangeal dorsal and palmar
cartilage [32]. Similarly, a detailed DECT
analysis of foot scans in people with
tophaceous gout has shown that urate crystal
deposition is as frequently located in tendon
sites as bone sites, and that certain tendons,
particularly the Achilles tendon and peroneal
tendons are more frequently affected [33]. Such
tendon involvement is often difficult to
appreciate on physical examination.
A further insight from imaging studies has
been the close relationship between MSU crystal
deposition and joint damage. In people with
advanced gout, bone erosion is a frequent
finding on plain radiography. In addition,
other structural damage including joint space
narrowing and features of new bone formation
such as bone sclerosis and spur formation are
frequently observed [34]. Conventional CT and
DECT studies have demonstrated the close
relationship between features of structural
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joint damage and urate deposition, with MSU
crystals frequently observed within areas of
bone erosion [34–36] (Fig. 3). Structural
change is a definite indication for urate-
lowering therapy. However, the recent reports
demonstrating a close relationship between
joint damage and MSU crystal deposition
emphasize the importance of strategies to
reduce crystal burden before structural damage
occurs.
The role of imaging in clinical management
of gout is rapidly changing, as we gain further
understanding about the various methods. Both
ultrasonography and DECT can play a role in
gout diagnosis, although diagnostic accuracy is
not perfect; a recent meta-analysis comparing
advanced imaging for gout with microscopic
diagnosis has reported a pooled sensitivity and
specificity of US double contour sign as 0.83
and 0.76, respectively; of US tophus as 0.65 and
0.80, respectively; and of DECT as 0.87 and
0.84, respectively [37]. Therefore, although
advanced imaging may assist with gout
diagnosis, in the situation of clinical
uncertainty, microscopic diagnosis remains
the gold standard. In clinical practice, imaging
can also play an important role in assessment of
disease complications, including involvement
of tendons/ligaments, spinal disease [38],
structural joint damage, and bone and soft
tissue infection that can mimic acute gout
flares. In the context of possible infection,
magnetic resonance imaging (MRI) can play a
particularly important role, with the presence
of MRI bone marrow edema strongly suggestive
of infection rather than gout [39]. Although the
costs and ionizing radiation of DECT preclude
the widespread use for serial monitoring of
disease in most clinical situations,
ultrasonography within the clinic may be a
particularly useful monitoring tool in a number
of clinical scenarios, including in patients who
have achieved target serum urate
concentrations but have ongoing symptomatic
disease, and in those who have incomplete
adherence to urate-lowering therapy [40, 41].
Both ultrasonography and DECT can also play
an important role in patient understanding of
disease both at the time of diagnosis and during
follow-up; visualization of crystals using
imaging methods allows the patient to
understand the central concept of gout as a
chronic disease of MSU crystal deposition, and
the need for long-term urate-lowering therapy
to reduce serum urate and ultimately achieve
dissolution of MSU crystals.
TREATING HYPERURICEMIA
IN GOUT: THE IMPORTANCE
OF GETTING TO TARGET
Strategies for treatment to target (T2T) have
become extremely popular lately in the case of
diverse diseases such as in diabetes,
hypertension, hyperlipidemia, and rheumatoid
arthritis. Targets have also been recommended
when facing the treatment of hyperuricemia in
gout, depending on actual clinical stage of
disease, but also for long-term treatment.
Fig. 3 Two-dimensional DECT sagittal image
demonstrating urate crystal deposition within an erosion
at the 1st metatarsophalangeal joint in a patient with
tophaceous gout. Urate crystals are shown in green
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The strategy to achieve gout ‘‘cure’’ [42] is
first to completely dissolve MSU crystals and
second, once no crystal burden is present, to
avoid new crystal formation [43]. The overall
strategy is based on tactical movements or
interventions to achieve strategic outcomes.
One of the first tactics to achieve victory
when facing patients with gout is to fully
understand, as health care providers, the
importance and impact of proper information
and proactive education of patients [44]. These
actions have been nicely shown to improve
adherence, avoid withdrawal of treatment and
reduce loss to follow-up. Time restriction in
clinics may jeopardize such an approach, but
investing time for definitive diagnosis,
information, and education will surely enhance
success [44].
Implementing anti-inflammatory
prophylaxis prior to or at the initiation of
urate-lowering treatment (ULT), generally for
6–12 months duration, to prevent the
occurrence of acute episodes of inflammation
(flares) should be seriously considered, and is
highly recommended [2, 45], although
medications and doses labeled may widely
differ among different countries. In addition,
patients should be instructed about how to
manage the acute episodes of inflammation
that may appear despite adequate prophylaxis,
mostly in the first year after initiating urate-
lowering therapy.
Reducing sUA levels to target is the main
strategic concept to ‘‘cure’’ gout [46] and is
pathophysiologically sound, inverting the
mechanism of MSU crystal formation. Different
targets have been recognized and these targets
may also differ considering the burden of
deposition, or stages of the natural progression of
the disease [47] and different stages of treatment,
initially dissolving pre-formed crystals, then
preventing new crystal formation [43].
Treating to target sUA comprises the concept
that ULT should reach and maintain steady
subsaturating sUA levels in plasma in the long
term [2, 3], that is sUA at least lower than 6 mg/
dl (360 lmol/L) in all patients with gout, as
there is compelling evidence that getting to this
minimum target is associated with reduction of
flares and tissue deposits [48]. Nevertheless, as
discussed in the 2006 European League Against
Rheumatism (EULAR) recommendations [2],
the 2012 American College of Rheumatology
(ACR) guidelines recommend that targeting
lower that 5 mg/dl (300 lmol/L) is required for
those patients with extensive MSU crystal
deposition on either clinical examination or
imaging studies [3], as the lower sUA levels
achieved, the more rapid reduction of deposits
in tissues [40, 49].
Although lifelong control of sUA to
subsaturating levels is recommended, the
previously cited recommendations and
guidelines do not approach whether these
targets should be maintained lifelong, that is,
after the last MSU crystal has dissolved due to
appropriate long-term ULT. On this point, some
patients may not need ULMs lifelong as after
long-term treatment they may show
subsaturating sUA levels [50]. Therefore, a two-
stage approach to urate lowering can be
designed: a first intensive urate-lowering
approach to completely dissolve MSU crystals,
and especially for those patients with extensive
deposition, and afterwards just keep sUA to just
below the saturation threshold lifelong. To
make it clear: ‘‘more is required to get it clean
than to keep it clean’’ [43].
ULMs are to be considered in patients with a
definite diagnosis of gout, the several guidelines
and recommendations differing in the clinical
starting point for prescribing ULMs.
Monotherapy with xanthine-oxidase inhibitors
has been recommended as first-line treatment,
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medications that exert uricosuric activity to be
added or to be considered in monotherapy if
the desirable initial target sUA is not achieved
[3]. Add-on regimens combining allopurinol
and probenecid [51] and allopurinol and
benzbromarone [49] have shown to further
reduce sUA, a fact that may be especially
useful to rapidly dissolve tophi [49]. Phase 1
and 2 clinical trials have also shown the
effectiveness in getting to target combining
lesinurad with allopurinol [52] and lesinurad
with febuxostat [53].
In summary, the prevalence of
hyperuricemia and gout is increasing,
deposition of MSU crystals and subclinical
inflammation being detected in advance of the
appearance of the first clinical symptom of
gout. The relationship of hyperuricemia, and
more clearly of gout, on cardiovascular
outcomes has raised increasing interest. The
usefulness of imaging techniques to evaluate
the presence and the extent of MSU crystal
deposition and as outcomes for urate-lowering
treatment looks promising, especially
ultrasonography and DECT. Such MSU crystal
deposits can be effectively and rapidly dissolved
with targeted urate-lowering therapy, and
neglecting a curable disease should be avoided.
The armamentarium to achieve such a goal has
increased in recent years and new medications
are in the pipeline.
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